KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals develops orally-delivered small molecule medicines, focusing on providing treatments for hereditary angioedema (HAE).

KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. | 7,687 followers on LinkedIn. Creating a new generation of small molecule protease inhibitors for HAE and DME. | KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our expertise to discover, develop and commercialize oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with sebetralstat, our first investigational product for hereditary angioedema (HAE), a rare genetic disease with debilitating attacks of tissue swelling that can be life threatening.

Manny Gaspar

Executive Director, Human Resources at KalVista Pharmaceuticals, Inc.

Kerrie Cutting

Peter Mutch

Executive Director, Head of Patient Services

Rachel Stay

Hear #KalVista ’s own Nicole Sweeny and Michael Smith speak with Linda, a person living with #HAE , about how our innovations are driven by the unmet needs of the HAE community.

#TeamKalVista had a successful #ACAAI24 ! We appreciate having the opportunity to speak with so many of you and extend a special thank you to everyone who attended our symposium focused on how physicians can address on-demand treatment behavior with their patients. See more of the work we shared: https://bit.ly/4hCmnHY .

Courage and compassion are at the heart of everything we do. Our courage drives us to innovate and push the boundaries of science, and our compassion reminds us that every patient, family, and community deserves the hope of new treatment options. If these values resonate, apply today to join #TeamKalVista : https://bit.ly/3NMR5R2 .

#TeamKalVista is here at #ACAAI24 ! Be sure to stop by booth #101 to learn more about how we’re advancing science to address the unmet need in #HAE . Also, don’t miss our symposium featuring Douglas Jones MD and Autumn Burnette on Sunday morning in Exhibit Halls C & D as well as our E-posters!

This past Saturday, members of #TeamKalVista joined the US Hereditary Angioedema Association (HAEA) in Chicago for an inspiring day of building #HAE awareness, making connections, and getting our steps in at the 2024 HAE IN-MOTION® awareness walk. Thank you to everyone who joined us!

Heading to #ACAAI24 ? So is #TeamKalVista ! Remember to visit booth #101 to meet with the team and learn more about our novel, scientific approach to tackling the unmet need in #HAE . We’re excited to see you there!

#TeamKalVista is thrilled to be a sponsor and participant at #ACAAI24 , hosted on October 24–28 in our backyard of Boston! From our booth and E-poster “Meet the Author” presentations to our symposium, we’ll be engaging with attendees all weekend long. Check out the E-poster schedule: https://bit.ly/3YbT7Pp

Learning to live with #HAE means being prepared to treat an attack at all times. Hear from Christina, a person living with HAE, for a firsthand account of the effects of delaying treatment.

Patients may delay treating #HAE with on-demand injectables due to fear of needles, avoiding pain from treatment, and lack of privacy to perform an injection. On-demand treatment options that are noninvasive have the potential to help patients better follow the recommended treatment guidelines. (Source: Valerieva A, Jones D, van Kooten S, Malloy N, Heckmann M, Betschel S. Treatment of HAE attacks with anticipated future oral on-demand therapies as reported by patients. Abstract presented at: EAACI Annual Meeting, May 31-June 3, 2024. Valencia, Spain. Allergy. In Press.)

On World Mental Health Day, we’re reminded that, for patients, anxiety often goes hand in hand with #HAE and its treatment. Having an attack management plan can help them feel prepared and make a difference in their wellbeing. Learn more about how you can support your patients’ needs: https://bit.ly/4f23cFn .

	Dec '13	Apr '15	Apr '16	Apr '17	Apr '18	Apr '19	Apr '20	Apr '21	Apr '22	Apr '23	Apr '24
revenue	415K -	1.80M 334.70%	2.13M 18.24%	1.50M 29.49%	8.39M 458.11%	16.13M 92.13%	12.69M 21.31%	12.69M 0%
cost of revenue											816K -
gross profit	415K -	1.80M 334.70%	2.13M 18.24%	1.50M 29.49%	8.39M 458.11%	16.13M 92.13%	12.69M 21.31%	12.69M 0%			-816K -
selling and marketing expenses											-816K -
general and administrative expenses	1.40M -	1.61M 14.69%	2.65M 64.99%	11.18M 321.30%	8.86M 20.71%	10.93M 23.29%	13.03M 19.25%	16.64M 27.69%	26.45M 58.96%	30.59M 15.69%	54.28M 77.41%
selling general and administrative expenses	1.40M -	1.61M 14.69%	2.65M 64.99%	11.18M 321.30%	8.86M 20.71%	10.93M 23.29%	13.03M 19.25%	16.64M 27.69%	26.45M 58.96%	30.59M 15.69%	53.46M 74.74%
research and development expenses	4.23M -	8.29M 95.91%	14.66M 76.96%	12.67M 13.61%	18.24M 43.98%	35.02M 92.03%	40.19M 14.77%	41.29M 2.72%	70.17M 69.95%	80.28M 14.41%	94.62M 17.87%
other expenses	-59K -	844K 1,530.51%	2.03M 141.00%	2.33M 14.50%	4.39M 88.58%	7.68M 74.91%	9.83M 27.96%	9.93M 1.01%	14.72M 48.26%	15.64M 6.26%
cost and expenses	5.63M -	9.89M 75.69%	17.31M 75.01%	23.84M 37.71%	27.10M 13.66%	45.95M 69.55%	53.22M 15.84%	57.92M 8.83%	96.61M 66.80%	110.87M 14.76%	148.90M 34.30%
operating expenses	5.63M -	9.89M 75.69%	17.31M 75.01%	23.84M 37.71%	27.10M 13.66%	45.95M 69.55%	53.22M 15.84%	57.92M 8.83%	96.61M 66.80%	110.87M 14.76%	148.08M 33.56%
interest expense	405K -	-863K 313.09%	-3.75M 333.95%	-3.74M 0.24%	-2.90M 22.38%	-9.18M 216.45%			1.09M -	-17.96M 1,748.07%
ebitda	-5.25M -	-8.05M 53.47%	-16.81M 108.78%	-23.67M 40.82%	-16.95M 28.39%	-29.49M 73.98%	-39.65M 34.46%	-58.23M 46.85%	-94.51M 62.30%	-110.24M 16.64%	-148.08M 34.32%
operating income	-5.22M -	-8.09M 55.08%	-15.18M 87.67%	-22.34M 47.15%	-18.70M 16.27%	-29.82M 59.42%	-40.53M 35.93%	-57.92M 42.90%	-96.61M 66.80%	-110.87M 14.76%	-148.90M 34.30%
depreciation and amortization	27K -	38K 40.74%	33K 13.16%	40K 21.21%	180K 350%	378K 110.00%	879K 132.54%	-310K 135.27%	2.10M 777.74%	628K 70.11%	816K 29.94%
total other income expenses net	-59K -	844K 1,530.51%	3.69M 337.80%	3.70M 0.14%	2.82M 23.84%	7.73M 174.34%	11.29M 46.07%	11.68M 3.42%	14.27M 22.22%	17.96M 25.85%	13.80M 23.17%
income before tax	-5.68M -	-7.23M 27.26%	-11.44M 58.26%	-18.60M 62.67%	-15.80M 15.04%	-20.69M 30.92%	-29.24M 41.31%	-46.24M 58.15%	-82.34M 78.05%	-92.91M 12.83%	-135.10M 45.41%
income tax expense	462K -	-863K 286.80%	-5.41M 526.42%	-5.11M 5.53%	-1.33M 74.04%	124K 109.35%	-124K 200%	-1.75M 1,311.29%	-13.83M 690.11%	-18.05M 30.57%	-8.45M 53.18%
net income	-5.68M -	-7.23M 27.26%	-11.44M 58.26%	-18.60M 62.67%	-15.80M 15.04%	-20.82M 31.71%	-29.12M 39.87%	-44.49M 52.82%	-68.51M 53.98%	-74.85M 9.26%	-126.64M 69.19%
weighted average shs out	724.80K -	263.36K 63.66%	591.30K 124.52%	4.65M 685.86%	10.32M 122.13%	15.08M 46.11%	17.75M 17.69%	19.09M 7.58%	24.47M 28.17%	27.89M 13.97%	36.79M 31.89%
weighted average shs out dil	724.80K -	263.36K 63.66%	591.30K 124.52%	4.65M 685.86%	10.32M 122.13%	15.08M 46.11%	17.75M 17.69%	19.09M 7.58%	24.47M 28.17%	27.89M 13.97%	36.79M 31.89%
eps	-7.83 -	-27.44 250.45%	-19.34 29.52%	-4 79.32%	-1.53 61.75%	-1.38 9.80%	-1.64 18.84%	-2.33 42.07%	-2.80 20.17%	-2.68 4.29%	-3.44 28.36%
epsdiluted	-7.83 -	-27.44 250.45%	-19.34 29.52%	-4 79.32%	-1.53 61.75%	-1.38 9.80%	-1.64 18.84%	-2.33 42.07%	-2.80 20.17%	-2.68 4.29%	-3.44 28.36%

COM:KALVISTA

KalVista Pharmaceuticals

Last Close

9.32

22/11 21:00

Market Cap

530.31M

Beta: -

Volume Today

405.00K

Avg: -

Preview